Steward Financial Group’s Xenon Pharmaceuticals XENE Stock Holding History

Steward Financial Group’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$0	Buy	+12	New	+$449	﹤0.01%	1589

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Steward Financial Group's XENE Position: Q3 2023 in Review

Steward Financial Group opened a new position in Xenon Pharmaceuticals (XENE) in Q3 2023: 12 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #1589 among its holdings.

180 funds tracked by Wall St. Rank hold XENE as of Q3 2023.

Steward Financial Group held 12 shares of Xenon Pharmaceuticals worth $0 as of Q3 2023.
Xenon Pharmaceuticals was a new Steward Financial Group position in Q3 2023.
Xenon Pharmaceuticals made up ﹤0.01% of Steward Financial Group's portfolio in Q3 2023, its #1589 holding.
180 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2023.

Based on Steward Financial Group's 13F filing for Q3 2023, filed 23 Oct 2023.